Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04978779 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome
A Phase 1 study, sponsored by Vincerx Pharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT04978779 is a Phase 1 study that was terminated before completion, run by Vincerx Pharma. The registered enrollment target is 6 participants.
The verdict
NCT04978779, a Phase 1 study, was terminated before completion, sponsored by Vincerx Pharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 as monotherapy or in combination with a BTKi in patients with Chronic Lymphocytic Leukemia (CLL) or Richter Syndrome
Interventions
- DRUG VIP152
- DRUG BTKi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-12-16 |
| Est. Completion | 2023-05-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04978779
The ClinicalTrials.gov registry entry for NCT04978779 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vincerx Pharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which VIP152 is the first listed.
NCT04978779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04978779 about?
NCT04978779 is a clinical study titled "A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome". Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 as monotherapy or in combination with a BTKi in patients with Chronic Lymphocytic Leukemia (CLL) or Richter Syndrome
What is the current status of trial NCT04978779?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2021-12-16. Estimated completion is 2023-05-26.
What interventions are being tested in trial NCT04978779?
The interventions under investigation include: VIP152 (DRUG), BTKi (DRUG).
Who is sponsoring clinical trial NCT04978779?
This trial is sponsored by Vincerx Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.